Breckenridge Eyes First Kyprolis Generic With FDA Approval
US Firm Received ANDA Approval With Partner Natco
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
You may also be interested in...
Natco Gets US Front-End Through Dash Acquisition
India’s Natco Pharma has struck an $18m deal to acquire New Jersey-based Dash Pharmaceuticals in a bid to acquire a “direct front-end marketing footprint” in the US.
Towa Follows Suit With Sawai To Steal Japanese Share From Nichi-Iko
Japanese player Towa Pharmaceutical joined Sawai in capitalizing on Nichi-Iko’s misery by taking market share from its rival, as it ran factories at full capacity and plotted for further expansion.
Sun Settles On Revlimid As Natco Scoops First ANDA Approval
Sun Pharma has become the latest ANDA sponsor to settle litigation with Celgene over Revlimid, shortly after Natco and partner Teva picked up the first ANDA approval for the blockbuster treatment for multiple myeloma.